• Wed, June 11, 2025
  • Thu, June 12, 2025
  • Fri, June 13, 2025
  • Sat, June 14, 2025
  • Sun, June 15, 2025
  • Mon, June 16, 2025
  • Tue, June 17, 2025

Are U.S. Pharma Companies Ready To Bring Life Science Manufacturing Home?

For the pharma industry, the question becomes: How can we properly prepare for reshoring while ensuring we're building tomorrow's manufacturing infrastructure today?
The article from Forbes Business Development Council, published on June 11, 2025, discusses the readiness of U.S. pharmaceutical companies to bring life science manufacturing back to the United States. It highlights the increasing interest in reshoring due to supply chain vulnerabilities exposed by global events like the COVID-19 pandemic. The piece examines the challenges and opportunities associated with this shift, including the need for significant investment in infrastructure, workforce development, and regulatory adjustments. It also notes the potential benefits such as enhanced control over production, reduced dependency on foreign suppliers, and the stimulation of local economies. The article concludes by emphasizing the importance of strategic planning and collaboration between government, industry, and academia to successfully transition life science manufacturing back to the U.S.

Read the Full Forbes Article at:
https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/2025/06/11/are-us-pharma-companies-ready-to-bring-life-science-manufacturing-home/